# Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection

> **NCT01742429** · PHASE4 · COMPLETED · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 200 (actual)

## Conditions studied

- Cure Rate of Helicobacter Pylori Infection

## Interventions

- **DRUG:** Proton pump inhibitor
- **DRUG:** Bismuth subsalicylate
- **DRUG:** Metronidazole
- **DRUG:** Tetracycline
- **DRUG:** Amoxicillin
- **DRUG:** Levofloxacin

## Key facts

- **NCT ID:** NCT01742429
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2014-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01742429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01742429, "Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01742429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*